Realtimekurse aktiv
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,955 | 0,995 | 08:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |
|---|---|---|---|---|
| Di | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | |
| Mo | Chemomab Therapeutics: Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25 | 1 | GlobeNewswire (USA) | |
| 15.05. | Chemomab Hikes on Q1 Figures | 3 | Baystreet.ca | |
| 15.05. | Chemomab Therapeutics GAAP EPS of -$0.01 in-line | 2 | Seeking Alpha | |
| 15.05. | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | |
| CHEMOMAB THERAPEUTICS Aktie jetzt für 0€ handeln | ||||
| 28.04. | Chemomab reports promising PSC treatment data | 3 | Investing.com | |
| 28.04. | Chemomab Therapeutics: Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases | 1 | GlobeNewswire (USA) | |
| 15.04. | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | |
| 04.04. | Chemomab Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 3 | SEC Filings | |
| 27.03. | Chemomab Therapeutics' Touts Positive Data From Experimental Drug For Chronic Liver Disease | 1 | Benzinga.com | |
| 27.03. | Chemomab Therapeutics: Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers | 151 | GlobeNewswire (Europe) | |
| 20.03. | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | |
| 03.03. | Chemomab Therapeutics GAAP EPS of -$0.01 | 1 | Seeking Alpha | |
| 03.03. | Chemomab Therapeutics Ltd. Q4 Loss Decreases | 2 | RTTNews | |
| 03.03. | Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update | 178 | GlobeNewswire (Europe) | |
| 03.03. | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | |
| 19.02. | Chemomab Therapeutics: Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis | 123 | GlobeNewswire (Europe) | |
| 19.02. | Chemomab Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | |
| 21.08.24 | Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update | 177 | GlobeNewswire (Europe) | |
| 26.07.24 | Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement | 143 | GlobeNewswire (Europe) |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
Das Unternehmen CHEMOMAB THERAPEUTICS LTD ADR kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,030 (+3,06 %) liegt der Kurs bei 1,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHEMOMAB THERAPEUTICS LTD ADR finden Sie auf Wallstreet Online.